Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer
L Groussin, J Clerc, O Huillard - New England Journal of …, 2020 - Mass Medical Soc
L Groussin, J Clerc, O Huillard
New England Journal of Medicine, 2020•Mass Medical SocRestoration of Iodine Uptake with Larotrectinib In a woman with thyroid cancer expressing
an EML4-NTRK3 fusion gene, the cancer had become refractory to radioactive iodine when
the capacity of the tumors to take up iodine was lost. The use of larotrectinib, an NTRK
inhibitor, resulted in a partial response and restored iodine uptake in the tumor cells.
an EML4-NTRK3 fusion gene, the cancer had become refractory to radioactive iodine when
the capacity of the tumors to take up iodine was lost. The use of larotrectinib, an NTRK
inhibitor, resulted in a partial response and restored iodine uptake in the tumor cells.
Restoration of Iodine Uptake with Larotrectinib
In a woman with thyroid cancer expressing an EML4-NTRK3 fusion gene, the cancer had become refractory to radioactive iodine when the capacity of the tumors to take up iodine was lost. The use of larotrectinib, an NTRK inhibitor, resulted in a partial response and restored iodine uptake in the tumor cells.
The New England Journal Of Medicine